Sep 15, 2026 08:37AM
Aug 17, 2026 08:30AM
Aug 4, 2026 08:04AM
Aug 4, 2026 08:00AM
Jul 30, 2026 08:31AM
Jul 30, 2026 08:31AM
Jul 13, 2026 08:01AM CEL-SCI launches phase 3 confirmatory study for head and neck cancer drug
Jul 13, 2026 08:00AM
Jun 24, 2026 08:00AM
Jun 24, 2026 08:00AM
Jun 16, 2026 04:01PM
Jun 16, 2026 04:01PM
Jun 16, 2026 08:02AM
Jun 16, 2026 08:00AM CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
Jun 15, 2026 03:02AM
Jun 14, 2026 07:03PM
Jun 12, 2026 08:00AM
Jun 12, 2026 08:00AM
May 18, 2026 08:00AM
May 13, 2026 03:00PM
May 13, 2026 03:00PM CEL-SCI Announces Closing of Public Offering
May 11, 2026 08:11PM
May 11, 2026 08:11PM
May 11, 2026 08:00AM
May 11, 2026 08:00AM
Feb 18, 2026 09:00AM
Dec 29, 2025 09:00AM
Aug 29, 2025 12:52PM CEL-SCI completes $10 million stock offering for drug development
Aug 29, 2025 12:52PM
Aug 27, 2025 10:35PM
Aug 27, 2025 10:35PM
Aug 27, 2025 05:25PM
Aug 27, 2025 05:25PM
Aug 14, 2025 10:45AM
Aug 13, 2025 09:17AM CEL-SCI files for breakthrough medicine status in Saudi Arabia
Aug 13, 2025 09:15AM
Jul 14, 2025 04:07PM
Jul 14, 2025 04:05PM
Jul 11, 2025 12:16PM
Jul 11, 2025 12:16PM
Jul 11, 2025 09:15AM
Jul 11, 2025 09:15AM CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
Jun 18, 2025 09:00AM
Jun 18, 2025 09:00AM
May 23, 2025 04:05PM
May 22, 2025 05:44AM
May 21, 2025 08:14PM
May 21, 2025 04:13PM
May 21, 2025 04:05PM CEL-SCI Announces Proposed Public Offering
May 21, 2025 08:08AM

334,166 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All